We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Prolactin is a polypeptide hormone that was discovered more than 70 years ago and is also known as the lactogenic hormone, lactotropin, luteotropic hormone, or luteotropin [1]. It was initially thought that it is only produced by the anterior pituitary gland and mainly involved with lactation, but increasing evidence suggests that there are other sources of prolactin and that it is involved in diverse essential biological activities [2].
Prolactin exerts many physiologic functions, perhaps the most prominent of which is inducing lobuloalveolar growth of the mammary gland, along with stimulation of lactogenesis or milk production after giving birth. The majority of prolactinomas contains only lactotroph cells and produce prolactin in excess. The major mechanism is a threefold increase in prolactin secretion, and a one-third decrease in metabolic clearance rate. Oligomenorrhea, amenorrhea, galactorrhea, infertility, hot flashes, vaginal dryness, headaches, and visual changes are clinical manifestations of hyperprolactinemia in premenopausal women. Women who have lactotroph microadenoma causing hyperprolactinemia and hypogonadism and cannot tolerate or do not respond to dopamine agonists and do not want to become pregnant can be treated with estrogen and progestin. Cabergoline is the most effective of the dopamine agonists but is the most expensive. Intravaginal administration of dopamine agonists reduces their side effects.
Hyperprolactinemia has a detrimental effect on fertility both in women and men, leading to galactorrhea anovulation, amenorrhea, oligomenorrhea, impotence, gynecomastia, and low semen profile. Men with hyperprolactinemia not only show abnormal semen analysis but also abnormal histological structure of the testicles with distorted seminiferous tubules and abnormal sertoli cells. Many physiological and or pathological changes involving lactotroph cells can result in hyperprolactinemia. The majority of prolactinomas contains only lactotroph cells and produce prolactin in excess. Antihypertensive drugs like methyldopa and reserpine increases prolactin secretion. A dopamine agonist drug should usually be the first line of treatment for patients with hyperprolactinemia of any cause including lactotroph adenomas of all sizes. Bromocriptine, cabergoline, pergolide are the available dopamine agonists to treat hyperprolactinemia. Dopamine agonists decrease prolactin secretion and reduce the size of the lactotroph adenoma in more than 90 percent of patients. Surgical and radiation treatment are also useful.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.